27 related articles for article (PubMed ID: 9859768)
1. Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells.
Lanza F; Latorraca A; Moretti S; Castagnari B; Ferrari L; Castoldi G
Cytometry; 1997 Jun; 30(3):134-44. PubMed ID: 9222099
[TBL] [Abstract][Full Text] [Related]
2. Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies.
Leong CF; Kalaichelvi AV; Cheong SK; Hamidah NH; Rahman J; Sivagengei K
Malays J Pathol; 2004 Dec; 26(2):111-6. PubMed ID: 16329563
[TBL] [Abstract][Full Text] [Related]
3. Detection of terminal transferase in acute myeloid leukemia by flow cytometry.
Paietta E; Meenan B; Heavey C; Thomas D
Cytometry; 1994 Jul; 16(3):256-61. PubMed ID: 7924695
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD10 immunoperoxidase staining of paraffin-embedded acute leukemias: comparison with flow cytometric immunophenotyping.
Bavikatty NR; Ross CW; Finn WG; Schnitzer B; Singleton TP
Hum Pathol; 2000 Sep; 31(9):1051-4. PubMed ID: 11014570
[TBL] [Abstract][Full Text] [Related]
5. Intracellular markers in acute myeloid leukemia diagnosis.
Koníková E; Glasová M; Kusenda J; Babusíková O
Neoplasma; 1998; 45(5):282-91. PubMed ID: 9921916
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of MPO and lysozyme antibodies in acute leukemia. Implications for the definition of FAB subtypes using a flow cytometric approach in combination with different permeabilising methods.
Latorraca A; Lanza F; Ferrari L; Castoldi GL
Eur J Histochem; 1997; 41 Suppl 2():27-8. PubMed ID: 9859768
[No Abstract] [Full Text] [Related]
7. Diagnostic pathways in acute leukemias: a proposal for a multimodal approach.
Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
Ann Hematol; 2007 May; 86(5):311-27. PubMed ID: 17375301
[TBL] [Abstract][Full Text] [Related]
8. The use of flow cytometry to detect minimal residual disease in acute leukemia.
Campana D; Coustan-Smith E
Eur J Histochem; 1996; 40 Suppl 1():39-42. PubMed ID: 8839698
[No Abstract] [Full Text] [Related]
9. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy.
Digiuseppe JA
Clin Lab Med; 2007 Sep; 27(3):533-49, vi. PubMed ID: 17658406
[TBL] [Abstract][Full Text] [Related]
10. AML-M0: a review of laboratory features and proposal of new diagnostic criteria.
Stasi R; Amadori S
Blood Cells Mol Dis; 1999 Apr; 25(2):120-9. PubMed ID: 10389594
[TBL] [Abstract][Full Text] [Related]
11. [Lysozyme and leukemia. Diagnostic, prognostic and pathogenic significance of lysozyme measurements].
Karle H; Hansen NE
Ugeskr Laeger; 1974 Oct; 136(44):2451-5. PubMed ID: 4608886
[No Abstract] [Full Text] [Related]
12. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
